Roche launches "future proof" Chlamydia test in Europe
This article was originally published in Clinica
Executive Summary
Roche Diagnostics has launched its Cobas TaqMan CT Test v2.0 in Europe. It CE marked the diagnostic, for detecting Chlamydia trachomatis, in June. Basel, Switzerland-based Roche claims the test is "future-proof", meaning it still produces reliable results even when mutations occur in the bacteria's cryptic plasmid DNA. It does this by simultaneously detecting two targets within the C trachomatis cryptic plasmid and genome target DNA. Plasmids are outside a bacteria's chromosomal DNA and are capable of replicating independently. The test is run on the Cobas TaqMan 48 analyser, which can carry out 48 tests per run with results available in 2.5 hours.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.